Journal of Clinical Lipidology
Volume 4, Issue 2 , Pages 83-88 , March 2010

When is equal not equal?

  • Allan D. Sniderman, MD

      Affiliations

    • Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Room H7.22, Royal Victoria Hospital, 687 Pine Avenue West, Montreal, Quebec H3A 1A1, Canada
    • Corresponding Author InformationCorresponding author.
    • ,
  • Ken Williams, PhD

      Affiliations

    • Department of Medicine, KenAnCo Biostatistics, University of Texas Health Science Center, San Antonio, TX, USA
    • ,
  • Matthew J. McQueen, MD, PhD

      Affiliations

    • Population Health Research Institute, McMaster University, Hamilton, ON, Canada
    • ,
  • Curt D. Furberg, MD, PhD

      Affiliations

    • Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC, USA

Received 18 December 2009 ,Accepted 24 January 2010.

References 

  1. Danesh J. The Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. J Am Med Assoc. 2009;302:1993–2000
  2. Sniderman AD, de Groot E, Couture P. ApoB and the atherogenic ApoB dyslipoproteinemias. In:  Kwiterovich PO editors. The Johns Hopkins Textbook of Dylipidemia. Philadelphia, PA: Lippincott Williams & Wilkins; 2009;p. 196–210
  3. McQueen MJ, Hawken S, Wang X, et al. The relative importance of lipids, lipoproteins, and apolipoproteins as risk markers associated with myocardial infarction in 52 countries. Lancet. 2008;372:224–233
  4. Parish S, Peto R, Palmer A, et al. The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls. Eur Heart J. 2009;30:2137–2146
  5. Barter PJ, Ballantyne CM, Carmena R, et al. ApoB versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med. 2006;259:247–258
  6. NHANES Investigators. NHANES Analytic Guidelines 2003–2004. Available at: http://www.cdc.gov/nchs/data/nhanes/nhanes_03_04/nhanes_analytic_guidelines_dec_2005.pdf. Accessed February 16, 2009.
  7. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Halit S, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–1847
  8. D'Agostino RB, Russell MW, Huse DM, Ellison RC, Silbershatz H, Wilson PW, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J. 2000;139:272–281
  9. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207
  10. Sniderman A, Williams K, Cobbaert C. ApoB versus non-HDLC: What to do when they disagree. Curr Atheroscler Rep. 2009;11:358–363
  11. Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373:1175–1182
  12. Sniderman AD, Tremblay A, Bergeron J, Gagne C, Couture P. Diagnosis of type III hyperlipoproteinemia from plasma total cholesterol, triglyceride, and apolipoprotein B. J Clin Lipidol. 2007;1:256–263
  13. de Graaf J, Couture P, Sniderman A. A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemias. Nat Clin Endocrinol Metab. 2008;4:608–618
  14. Cromwell WC, Otvos JD, Keyes MJ, et al. LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study—Implications for LDL management. J Clin Lipidol. 2007;1:583–592

PII: S1933-2874(10)00044-9

doi: 10.1016/j.jacl.2010.01.005

Journal of Clinical Lipidology
Volume 4, Issue 2 , Pages 83-88 , March 2010

Article Tools

* Image Usage & Resolution